Chemically Programmed Immunity

化学编程免疫

• 批准号: 8699729
• 负责人: PHILIP E DAWSON
• 金额: $ 42.02万
• 依托单位: SCRIPPS RESEARCH INSTITUTE, THE
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-09-30 至 2015-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8699729
• 关键词: Antibodies; Biomedical Research; Cells; Chemicals; Development; Disease; Flu virus; Goals; HIV-1; Immune; Immune response; Immune system; Immunity; Immunoglobulins; Infection prevention; Learning; Malignant Neoplasms; Natural Immunity; Receptor Signaling; Research; Scientist; T-Lymphocyte; Therapeutic; Toll-like receptors; Vaccines; Virus; abstracting; acquired immunity; arm; cancer therapy; fighting; flu; insight; interest; macrophage; meetings; novel; novel strategies; novel vaccines; pathogen; pill; programs; prophylactic; response; swine flu; tumor

DESCRIPTION Abstract: Imagine calling T-cells, macrophages, and antibodies into action by taking a simple pill that instantaneously programs both adaptive and innate arms of the immune system to attack a tumor or virus, preventing infection and halting disease. Such an approach could meet major unmet challenges in biomedical research and therapy. My goal is to develop novel approaches that allow innate and acquired immunity to be purposefully targeted to pathogens of interest. These studies build on recently revealed mechanisms of Toll-like receptor signaling, ideas concerning approaches of targeting their sensing abilities to pathogens of defined interest and insights gained from our own invention of chemically programmed antibodies. Ultimately, these studies will allow scientists to program a variety of immune cells and responses to attack pathogens of interest using a variety of mechanisms. We will apply these results to studies in cancer therapy. Furthermore, we will explore novel approaches that should allow for circulating immunoglobulins induced with covalent vaccines to be programmed to inhibit HIV-1 and flu virus entry. The vaccines that result from these studies may be of both prophylactic and therapeutics utility. I will develop novel chemical approaches aimed at learning how to purposefully target innate immunity, T- cells, and macrophages to defined pathogens. I will apply these developments to create new cancer therapies. I will develop a novel approach to orally available chemically programmed immunity. I will apply developments in orally available chemically programmed immunity towards new vaccine strategies for HIV-1 and flu.

描述

项目成果

Genome engineering with custom recombinases.

使用定制重组酶进行基因组工程。

• DOI: 10.1016/b978-0-12-801185-0.00004-0
• 发表时间: 2014
• 期刊: Methods in enzymology
• 作者: Gaj,Thomas;Barbas3rd,CarlosF
• 通讯作者: Barbas3rd,CarlosF

N-Sulfonyl-β-lactam hapten as an effective labeling reagent for aldolase mAb.

N-磺酰基-β-内酰胺半抗原作为醛缩酶单克隆抗体的有效标记试剂。

• DOI: 10.1016/j.bmcl.2015.03.011
• 发表时间: 2015
• 期刊: Bioorganic & medicinal chemistry letters
• 影响因子: 2.7
• 作者: Inokuma,Tsubasa;Fuller,RobertaP;Barbas3rd,CarlosF
• 通讯作者: Barbas3rd,CarlosF

In vivo programming of endogenous antibodies via oral administration of adaptor ligands.

• DOI: 10.1016/j.bmc.2017.09.010
• 发表时间: 2017-11
• 期刊: Bioorganic & medicinal chemistry
• 影响因子: 3.5
• 作者: M. Nagano;Nancy Carrillo;N. Otsubo;W. Hakamata;Hitoshi Ban;Roberta P. Fuller;Nasir K. Bashiruddin;C. Barbas

Human Serum Albumin Domain I Fusion Protein for Antibody Conjugation.

• DOI: 10.1021/acs.bioconjchem.6b00432
• 发表时间: 2016-10-19
• 期刊: Bioconjugate chemistry
• 影响因子: 4.7
• 作者: Patterson JT;Wilson HD;Asano S;Nilchan N;Fuller RP;Roush WR;Rader C;Barbas CF 3rd
• 通讯作者: Barbas CF 3rd

Improving the serum stability of site-specific antibody conjugates with sulfone linkers.

• DOI: 10.1021/bc500276m
• 发表时间: 2014-08-20
• 期刊: BIOCONJUGATE CHEMISTRY
• 影响因子: 4.7
• 作者: Patterson, James T.;Asano, Shigehiro;Li, Xiuling;Rader, Christoph;Barbas, Carlos F., III
• 通讯作者: Barbas, Carlos F., III